Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06489184 |
| The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China |
| unknown |
| — |
| 490 |
| Peking University People's HospitalOTHER |
| 1 |
| Jul 5, 2024 |
| clinicaltrials |
| NCT01346020 | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | unknown | — | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05371392 | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia | unknown | — | 80 | Sohag UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06379282 | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia(HIT-CLL) | unknown | N/A | 132 | University of SurreyOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06084923 | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | unknown | — | 73 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05803395 | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | unknown | — | 954 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT02229422 | A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)(GA101 & HDMP) | unknown | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05899543 | Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05888701 | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | unknown | — | 30 | University of Milano BicoccaOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05360758 | Ibrutinib Adapted to Response in Patients With CLL | unknown | — | 80 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03529227 | Gazyva Infusion Reaction Investigation(GAIRI) | unknown | — | 104 | Healthy FutureOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | unknown | N/A | 23 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05145101 | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia(Pneumo-CLL) | unknown | — | 150 | Hannah Garcia GarridoOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT04616274 | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04862806 | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | unknown | N/A | 1,000 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 17, 2021 | clinicaltrials |
| NCT04746092 | The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 | unknown | — | 630 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 16, 2021 | clinicaltrials |
| NCT04370457 | MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies | unknown | N/A | 300 | Centre for Research and Technology HellasOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT04980859 | Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation | unknown | Phase 3 | 45 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jul 28, 2021 | clinicaltrials |
| NCT04952974 | B-cell Chronic Lymphoid Malignancies Markers(MALYZOMA-II) | unknown | — | 420 | University Hospital, Strasbourg, FranceOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT01976520 | Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | unknown | Phase 1 | 30 | XEME Biopharma Inc.INDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04796675 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | unknown | Phase 1 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04814004 | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors | unknown | Phase 1 | 20 | Kai Lin Xu; Jun Nian ZhengOTHER | 1 | Mar 29, 2021 | clinicaltrials |
| NCT04691765 | Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients(Anakinra) | unknown | Phase 1 | 12 | Dr. David SpanerOTHER | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04796688 | Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03197259 | Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study(CLLTRegistry) | unknown | — | 1,000 | Fatih Demirkan, MDOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04747093 | Induced-T Cell Like NK Cells for B Cell Malignancies | unknown | Phase 1 / Phase 2 | 12 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04516551 | Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT | unknown | Phase 1 | 18 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04407845 | Atrial Fibrillation in Patients Receiving Ibrutinib(FABRIC) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT01619761 | NK Cells in Cord Blood Transplantation | unknown | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03633045 | Observational Study of Ibrutinib Use in CLL | unknown | — | 70 | Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of HealthOTHER | 1 | Feb 10, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials